Page 721«..1020..720721722723..730740..»

Category Archives: Transhuman News

Woman Claims She Has DNA Evidence to Prove She is Girl Who Went Missing in 2000 – Newsweek

Posted: October 11, 2021 at 10:20 am

A woman in Indiana is claiming she has DNA evidence proving she is a girl who went missing 21 years ago in Virginia.

Kaylynn Stevenson, of Fort Wayne, Indiana claimed she has DNA evidence proving she is Brittany Renee Williams, a girl who went missing at the age of seven back in 2000, WWBT reported.

Williams disappeared from her independent foster care under the guardianship of a woman named Kim Parker back in 2000. When Williams stopped showing up to school and court hearings with Parker, Henrico Police started an investigation at Parker's home in Virginia.

The National Center for Missing and Exploited Children reported that the number of children missing from state care has increased over the years. Most of these children were not reported missing until federal legislation was passed in 2014 requiring state agencies to report a missing or abducted child to law enforcement and NCMEC "24 hours of receiving information about a missing child under their care," according to NCMEC.

The NCMEC also places children who've been missing for over six months in the "long term missing category" and estimated that only about 150 children were found after missing for a decade or longer. Williams has been missing for 21 years.

According to WWBT, Williams was born with AIDS, and authorities were worried the girl was dead because she did not have her medication. Allegedly Parker attempted to give Williams to Williams' adult half-sister because she was unable to care for her. Williams' sister declined and Parker told authorities she paid two women in California to take Williams. But both women said they never had custody of Williams and did not know where she was.

Stevenson told WWBT that she did not remember many details about her childhood except that she lived with her adoptive parents in Ohio and her surname was Williams. She said her memory is spotty but she also has scars from catheters and an eating tube. On the missing person poster for Williams, catheter scars were written under distinguishing characteristics.

While Stevenson doesn't remember a lot about her childhood, she said she does have a DNA sample taken at a LabCorp that proves she is the missing girl from 2000. She also has scattered memories from her time at Parker's foster home called Rainbow Kids.

According to court documents, Parker was indicted on 73 counts of fraud and was accused of taking over $24,000 in government benefits that were meant to go to Williams. Multiple people who knew Parker also said the house was "filthy" and some worried about neglect. WWBT reported that Parker took a plea deal and spent 10 years behind bars.

WWBT reported that Stevenson began researching her biological family when she came across a photo of the missing seven-year-old girl from Virginia.

"And Brittany Renee Williams' photo popped up," Stevenson told WWBT. "I woke my wife up out of her sleep and was like, 'This is me! I know me when I see me. This is me!'"

But there were several factors that still didn't line up. Stevenson said she has blood work proving she does not have AIDS. She also said the birth certificate that her adopted parents showed her does not match the birthday of Williams.

WWBT reported that the FBI and Henrico Police are investigating Stevenson's DNA sample against the other living daughter of Rose Marie Thompson, Williams' biological mother. Stevenson told WWBT she is now going by Brittany because she doesn't want any "ties to my adoptive name. That is not me."

Read more:
Woman Claims She Has DNA Evidence to Prove She is Girl Who Went Missing in 2000 - Newsweek

Posted in DNA | Comments Off on Woman Claims She Has DNA Evidence to Prove She is Girl Who Went Missing in 2000 – Newsweek

In Focus podcast | India’s first DNA vaccine has been approved for use in children: What you need to know about it – The Hindu

Posted: at 10:20 am

As early as this month, India may see the rollout of ZyCoV-D, the world's first DNA vaccine against COVID-19. Pharmaceutical company Zydus Cadila has received Emergency Use Authorisation for this vaccine, which is also the first in the country to be approved for children above the age of 12.

How do DNA vaccines work, and how are they different from the vaccines we have now -- Covishield and Covaxin? What sort of immunity will the DNA vaccine provide? Will the three-dose regimen pose a problem, logistically, in administering ZyCoV-D?

Sero-surveys across the country have shown us that in the most populated of regions, 70% of the population may have COVID-19 antibodies already -- what does this mean for children, and do they need to be necessarily vaccinated at this stage?

Guest: Dr Gagandeep Kang,Professor of Microbiology at Christian Medical College, Vellore.Host:ZubedaHamid

Read more:
In Focus podcast | India's first DNA vaccine has been approved for use in children: What you need to know about it - The Hindu

Posted in DNA | Comments Off on In Focus podcast | India’s first DNA vaccine has been approved for use in children: What you need to know about it – The Hindu

We Think Sonos (NASDAQ:SONO) Might Have The DNA Of A Multi-Bagger – Simply Wall St

Posted: at 10:20 am

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. With that in mind, the ROCE of Sonos (NASDAQ:SONO) looks great, so lets see what the trend can tell us.

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. Analysts use this formula to calculate it for Sonos:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) (Total Assets - Current Liabilities)

0.29 = US$198m (US$1.1b - US$401m) (Based on the trailing twelve months to July 2021).

Thus, Sonos has an ROCE of 29%. That's a fantastic return and not only that, it outpaces the average of 15% earned by companies in a similar industry.

View our latest analysis for Sonos

In the above chart we have measured Sonos' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

The fact that Sonos is now generating some pre-tax profits from its prior investments is very encouraging. Shareholders would no doubt be pleased with this because the business was loss-making four years ago but is is now generating 29% on its capital. Not only that, but the company is utilizing 315% more capital than before, but that's to be expected from a company trying to break into profitability. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, both common traits of a multi-bagger.

On a related note, the company's ratio of current liabilities to total assets has decreased to 37%, which basically reduces it's funding from the likes of short-term creditors or suppliers. This tells us that Sonos has grown its returns without a reliance on increasing their current liabilities, which we're very happy with.

To the delight of most shareholders, Sonos has now broken into profitability. And with the stock having performed exceptionally well over the last three years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.

One more thing, we've spotted 2 warning signs facing Sonos that you might find interesting.

Sonos is not the only stock earning high returns. If you'd like to see more, check out our free list of companies earning high returns on equity with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

See the original post:
We Think Sonos (NASDAQ:SONO) Might Have The DNA Of A Multi-Bagger - Simply Wall St

Posted in DNA | Comments Off on We Think Sonos (NASDAQ:SONO) Might Have The DNA Of A Multi-Bagger – Simply Wall St

DNA Ligase Market Report Covers Future Trends With Research 2021-2028 | Thermo Fisher Scientific, Hoffmann-La Roche, Agilent Technologies EcoChunk -…

Posted: at 10:20 am

A2Z Market Research announces the release of DNA Ligase Market research report. The market is predictable to grow at a healthy pace in the coming years. DNA Ligase Market 2021 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market.

DNA ligase offers a connection between two strands of DNA by creating a bond between the deoxyribose group of one strand and the phosphate group on another. DNA ligase is an enzyme whereas during DNA replication there is the formation of lagging strand on which Okazaki fragments are presents separately and DNA ligase utilize to gather that fragments.

The top companies in this report include:

Thermo Fisher Scientific, Hoffmann-La Roche, Agilent Technologies, Promega Corporation, New England Biolabs, Merck & Co., Amano Enzyme, BASF SE, Novozymes A/S, Codexis.

Get Sample Report with Latest Industry Trends Analysis: https://www.a2zmarketresearch.com/sample-request/571718

As analytics have become an inherent part of every business activity and role, form a central role in the decision-making process of companies these days is mentioned in this report. In the next few years, the demand for the market is expected to substantially rise globally, enabling healthy growth of the DNA Ligase Market is also detailed in the report. This report highlights the manufacturing cost structure includes the cost of the materials, labor cost, depreciation cost, and the cost of manufacturing procedures. Price analysis and analysis of equipment suppliers are also done by the analysts in the report.

This research report represents a 360-degree overview of the competitive landscape of the DNA Ligase Market. Furthermore, it offers massive data relating to recent trends, technological advancements, tools, and methodologies. The research report analyzes the DNA Ligase Market in a detailed and concise manner for better insights into the businesses.

The report, with the assistance of nitty-gritty business profiles, project practicality analysis, SWOT examination, and a few different insights about the key organizations working in the DNA Ligase Market, exhibits a point-by-point scientific record of the markets competitive scenario. The report likewise displays a review of the effect of recent developments in the market on markets future development prospects.

Global DNA Ligase Market Segmentation:

Market Segmentation: By Type

CloningMutation DetectionNext Generation SequencingDrug Target

Market Segmentation: By Application

CloningMutation DetectionNext Generation SequencingDrug Target

Geographic analysis:

The global DNA Ligase market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

Get Exclusive Discount on this Premium Report: https://www.a2zmarketresearch.com/discount/571718

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability DNA Ligase Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide DNA Ligase refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide DNA Ligase market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the DNA Ligase makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole DNA Ligase inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Link:
DNA Ligase Market Report Covers Future Trends With Research 2021-2028 | Thermo Fisher Scientific, Hoffmann-La Roche, Agilent Technologies EcoChunk -...

Posted in DNA | Comments Off on DNA Ligase Market Report Covers Future Trends With Research 2021-2028 | Thermo Fisher Scientific, Hoffmann-La Roche, Agilent Technologies EcoChunk -…

Little Mix reveal all about The X Factor, the curse of the girl band and DNA | The Power of Little Mix Podcast – PopBuzz

Posted: at 10:20 am

11 October 2021, 08:35

Jade Thirlwall, Leigh-Anne Pinnock and Perrie Edwards open up about The X Factor, DNA and so much more.

The first episode of The Power of Little Mix is out now, a podcast created to celebrate a decade of making girl group history.

In 'The Curse Of The Girl Band, Jade Thirlwall, Leigh-Anne Pinnock and Perrie Edwards open up about the first two years of their career. The girl group discuss how they overcame The X Factor's infamous 'girl band curse', and how they proved that their wings really were made to fly with their record-breaking debut album.

We also find out about the origins of the band when host Sam Prance (that's me again guys) chats with Beth Honan, Little Mixs creative director on The X Factor, and Iain James, the co-writer behind some of the girls' biggest hits.From their formation in 2011 to the end of the DNA era, this is how the legend of Little Mix began.

READ MORE: 10 iconic Little Mix songs that should have been singles

Check out a sneak peek of the episode below and make sure to download and subscribe on Global Player to listen in full.

Sam Prance: So to start, we're gonna take it right back to 2011. I want to take you to the moment that Kelly and Tulisa put you together. What actually happened right after the cameras were cut and you'd been told we want you to be a girl group?

Leigh-Anne Pinnock: Well, we got to know each other. We went off to a pub that Perrie used to own and got to know each other and realise that we were gonna be the next big thing. But we just sang together and it was magic. And it was just meant to be. Like, we knew it was meant to be.

Sam Prance: Was there a first song you sang together and harmonised and you were just like, Wow, this is magic!?

Jade Thirlwall: Yeah, I think, was it 'Cry Me a River'?

Perrie Edwards: Yeah, it would have been that. Yeah. Yeah.

Leigh-Anne Pinnock: Or was it Ed Sheeran? You Need Me'?

Jade Thirlwall: Well, maybe

Leigh-Anne Pinnock: No, it was 'Cry Me a River'.

Perrie Edwards: I think it was 'Cry Me a River' or the, what's his name, 'And now you say you're lonely, you cried the whole night through'? Like the arrangement we did. The thing is we hung out for so long, getting to know each other, becoming best friends, sisters, like just having a laugh. And then we were like, 'We haven't actually sang anything yet, should we rehearse?' And then that's when we sang together and we were like. I remember Jade's face. And our mams were literally like, 'Oh my God'! Like, they couldn't believe it. They were so shocked. Weren't they? I think we were shocked as well.

Sam Prance: And you went straight from that, and got through straight to the live shows. But there was sort of this narrative when you started that you were the underdogs. You were the bookies favourite to go out in the first week, there was the girl group curse, you had to change your name halfway through... How was the stress of that?

Jade Thirlwall: Oh, it was like the weight of the world was on our shoulders?

Perrie Edwards: Literally!

Jade Thirlwall: No, do you know what, I think we've really thrived well under this sort of underdog mentality. You know, we've always had a point to prove whether it's from right at the beginning as a girl band like you say. As the weeks went on, we just kept having to prove why we deserved to be there and I think that mentality has never sort of left us our whole career. And I feel like that's probably why we're still going strong. But yeah, it was a lot man, especially back then. We were like 18/19, thrown into the limelight, thrown onto a show like that. It's so intense. I feel kind of grateful that we were so young and naive to it all because we were just literally like, just bouncing off the walls, weren't we? We didn't really understand fully what was going on until we were just in it. which was probably for the best to be honest, to not have to overthink it all.

The Power of Little Mix is available to stream exclusively on Global Player now.

Visit link:
Little Mix reveal all about The X Factor, the curse of the girl band and DNA | The Power of Little Mix Podcast - PopBuzz

Posted in DNA | Comments Off on Little Mix reveal all about The X Factor, the curse of the girl band and DNA | The Power of Little Mix Podcast – PopBuzz

Scientists reconstruct faces of Egyptian mummies using ancient DNA – The Indian Express

Posted: at 10:20 am

About 2000 years, how did the Egyptians look like? Did they have dark skin and curly hair? A Virginia-based lab has now recreated the faces of three mummies using their DNA. The three men were predicted to have a light brown complexion, with dark eyes and hair and no freckles.

Their findings were published last month at the International Symposium on Human Identification held in Florida, US.

Parabon NanoLabs predicted the faces of mummies that belonged to an ancient Nile community called the Abusir el-Meleq. This site is believed to have been inhabited from at least 3250 BC to 700 CE. Studies have shown that this area was of great religious significance. They were devoted to Osiris or the god of the dead.

In 2017, researchers from Germany published a paper in Nature detailing how they extracted the ancient DNA from these mummies and what the genomes suggest about their ancestry.

Using this DNA, Parabon NanoLabs carried out a comprehensive study and used the information to reconstruct the faces. The company writes that this is the first time comprehensive DNA phenotyping has been performed on human DNA of this age.

The lab used new models to predict the ancestry, skin pigmentation, and face morphology of the three mummies. Interestingly, their ancestry was determined to be more similar to the modern Mediterranean and Middle Eastern individuals than to modern Egyptians.

These results were similar to the 2017 paper which wrote that ancient Egyptians shared more ancestry with Near Easterners than present-day Egyptians, who received additional sub-Saharan admixture in more recent times.

The forensic artist created the likely appearance of the mummies at age 25. They used special three-dimensional face morphology studies to predict principal components of the faces such as the size of the head, the distance between facial features.

Parabon bioinformatician Dr Janet Cady, who spearheaded the work, said in a release that this new imputation technology can also help study challenging forensic samples.

Here is the original post:
Scientists reconstruct faces of Egyptian mummies using ancient DNA - The Indian Express

Posted in DNA | Comments Off on Scientists reconstruct faces of Egyptian mummies using ancient DNA – The Indian Express

These Researchers Have Found A New Way To Record Data To DNA Within A Few Minutes – Wonderful Engineering

Posted: at 10:20 am

Global data output will exceed 463 exabytes per day by 2025, according to the World Economic Forum. Our existing data storage systems, which necessitate massive amounts of energy and space, are finite, leaving us on the verge of a catastrophic data-storage dilemma. Since our genetic code is typically much more efficient at storing information than existing approaches, DNA-based data storage could be a viable replacement for hard drives.

Northwestern University researchers have introduced a novel approach for storing information to DNA that takes only a few minutes.

The team of researchers used a revolutionary enzyme approach to produce DNA that stores fast-evolving environmental cues directly into its sequences. This technique has the potential to transform the way scientists analyse and record brain neurons.

Scientists rely on multipart mechanisms that incorporate new information with existing DNA sequences to record intracellular molecular and digital data to DNA. This implies that for correct recording, they must activate and inhibit the expression of particular proteins for proper recording, which can take up to 10 hours.

The researchers projected that by utilising a new method known as Time-sensitive Untemplated Recording using Tdt for Local Environmental Signals, or TURTLES, they could accelerate the process. So instead of copying a DNA template, they would create an entirely new DNA. The procedure took only a few minutes to record the information into the genetic code.

Nature is good at copying DNA, but we really wanted to be able to write DNA from scratch, Keith E.J. Tyo, the papers senior author, said. The ex vivo (outside the body) way to do this involves a slow, chemical synthesis. Our method is much cheaper to write information because the enzyme that synthesizes the DNA can be directly manipulated. State-of-the-art intracellular recordings are even slower because they require the mechanical steps of protein expression in response to signals, as opposed to our enzymes which are all expressed ahead of time and can continuously store information.

This could be a viable approach for tackling the rapid expansion in data storage requirements while advancing brain research. This is a really exciting proof of concept for methods that could one day lets us study the interactions between millions of cells simultaneously, said Namita Bhan, studys co-author.

If you look at how current technology scales over time, it could be decades before we can even record an entire cockroach brain simultaneously with existing technologieslet alone the tens of billions of neurons in human brains, said co-author Alec Callisto. So thats something wed really like to accelerate.

Currently, the researchers are progressing towards the genomic infrastructure and cellular techniques needed for reliable intracellular recording, and they believe that other engineers will keenly employ the method to capture signals for their own study.

Read more here:
These Researchers Have Found A New Way To Record Data To DNA Within A Few Minutes - Wonderful Engineering

Posted in DNA | Comments Off on These Researchers Have Found A New Way To Record Data To DNA Within A Few Minutes – Wonderful Engineering

ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa – PRNewswire

Posted: at 10:17 am

SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021, at 10:15 a.m. PT in Carlsbad, CA.

Michael Yang, ViaCyte's President and Chief Executive Officer, will give an update on the Company's latest advances in the development of product candidates for long-term treatment of type 1 diabetes, to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications.

"Cell replacement therapy has the potential to address the limitations of current therapies and advance the treatment of diabetes," said Mr. Yang. "Recently, ViaCyte has demonstrated a clinical proof-of-concept that our stem cell-derived islet replacement therapy is a promising approach to effectively produce insulin and regulate blood glucose in patients with type 1 diabetes."

The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.For more details, visit http://www.meetingonthemesa.com.

About ViaCyte

ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. ViaCyte has the opportunity to use these technologies to address critical human diseases and disorders that can potentially be treated by replacing lost or malfunctioning cells or proteins. The Company's first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. For more information, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

SOURCE ViaCyte, Inc.

See the original post here:
ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire

Posted in Gene Medicine | Comments Off on ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa – PRNewswire

CRISPR is revolutionizing medicine its origin story is pretty incredible, too – Freethink

Posted: at 10:17 am

Science is a lot more boring than it is commonly portrayed. Movies often show montages of bespectacled scientists scribbling notes (probably on a chalkboard) before they finally punch the air in delighted revelation. Or maybe they show a huge team of researchers spending years on some scientific problem, and then the protagonist turns a blueprint upside down and says, but could this be it? Everyone is amazed.

The reality of science is far more prosaic. It is years upon years of hard graft, dead ends, worrying about funding, conferences, more dead ends, more hard graft, and awholelot of collaboration. Science is less about eureka moments and lone geniuses and more about standing on the shoulders of giants. But occasionally, a development bucks the trend, giving at least some validation to the Hollywood tropes.

One example is in the truly revolutionary gene-editing technology known as CRISPR. The tool is incredible not just for what it can do and how it might change human life, but also for its origin story a tale of a game-changing discovery, a eureka moment, and research conducted for researchs sake.

The story starts in 1987 when a Japanese research team headed by Yoshizumi Ishino was researching the microbe E. coli. They wanted to explore a peculiar gene called iap. This mysterious gene was unique, consisting of blocks of five identical segments of DNA divided by unique spacer DNA. But because this was the 1980s and the technology wasnt sophisticated yet, the Osaka team didnt really know what to make of the observations, or what to do with them.

Fifteen years later in the Netherlands, a team headed by Francisco Mojica and Ruud Jansen of Utrecht University renamed these sandwiches of iap to CRISPR, which means clustered regularly interspaced short palindromic repeats. What Mojica, Jansen et al. discovered was remarkable: These genes encoded enzymes that couldcut DNA. Still, no one knew why this happened, and the implications of this werent fully appreciated.

What they discovered is that the CRISPR system could be reprogrammed to cut and paste not only virus DNA, but also whatever isolated DNA they wanted.

Three years later, Eugene Koonin at the National Center for Biotechnology Information, noticed that these unique DNA bits in the spacers looked remarkably like viruses. And so, Koonin theorized that certain microbes were using CRISPR as a defense mechanism. It was a bacterial immune system. He suggested that bacteria used CRISPR (and their cas enzymes) to take fragments of invasive viruses and then paste them into their own cut DNA, where they acted as a kind of bacterial vaccination against future viruses, or like an immune-system memory.

It was left for microbiologist Rodolphe Barrangou to prove Koonin right. CRISPR really was cutting and pasting DNA.

The implications of this were rather lost on both Barrangou and the microbiologist community. Barrangou himself used (and monetized) this technology to make virus-resistant bacteria for his yogurt-making employer Danisco. But on the other side of the country, at the University of Berkeley, these findings were being read by two people who would transform CRISPR technology: Jennifer Doudna and Emmanuelle Charpentier.

Doudna and Charpentier were experts in the field of RNA the blueprints created by DNA that act as the messenger required to encode all the proteins of life. What they discovered is that the CRISPR system could be reprogrammed to cut and paste not only virus DNA, but also whatever isolated DNA they wanted. They published their findings in a now-famous2012Sciencearticle.

But what does reprogram actually mean? First, we have to understand that CRISPR not only cuts and pastes virus DNA into its own DNA (as an immune-memory system or look-up table), but also uses this information to cut up future invader viruses, which prevents them from replicating. It does this by releasing RNA matching the virus DNA (which it has stored)along withits own cas enzyme. If these two find any invader virus DNA, they latch on, and the cas enzyme cuts it in two. Its an incredibly clever process.

This finding produced the eureka moment: Oh my gosh, this could be a tool! Doudna recalled. To make that tool, they simply needed to attach this casenzyme to an RNA of their own choosing, so that the enzyme would find and cut the matching DNA to that RNA. Its sort of like a microbial find and cut function. Whats more, they could then induce a cell to stitch genes to fill the gap a type of find and replace function.

The implications of what Doudna and Charpentier discovered have opened new and unprecedented opportunities. Since their original 2012 paper,an increasing number of companiesand research operations have been conjuring up exciting ways to apply CRISPR technology. Not only does it have huge application in biomedical fields, such as targeting the protein dystrophin responsible for many types of muscular dystrophy, but it also could transform agriculture, energy, and evenmammoth rewilding.

As with any new technology, there are dangers and ethical questions surrounding the use of CRISPR, especially concerning the prospect of creating designer babies. In 2018, the issue stepped out of the theoretical realm when the Chinese scientist He Jiankui edited human embryos for the first time in history, in an attempt to make the babies resistant to the HIV virus. (He was sentenced to three years in prison.) Arguably, these are normal calibration issues that society must deal with when faced with a revolutionary technology.

Whats doubly great about CRISPR is the story behind it. Across decades and continents, the story has involved accident, eureka, and out-of-the-box thinking. But its important to note that the research was done for its own sake. It was conducted to study E. coli, to examine bacterial immune systems, and to develop stronger yoghurt cultures, all while, in the words of Jennifer Doudna, not trying to get to a particular goal, except understanding. The research ultimately accomplished much more than that.

This article was originally published on our sister site, Big Think. Read the original article here.

Read more from the original source:
CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink

Posted in Gene Medicine | Comments Off on CRISPR is revolutionizing medicine its origin story is pretty incredible, too – Freethink

Longevity Foundation to Fund Geroscience Research with 860M – Labiotech.eu

Posted: at 10:17 am

The newly-created Longevity Science Foundation aims to extend the human lifespan to more than 120 years by channeling over 860M ($1B) into early-stage geroscience research in the next decade. Experts say thats a worthy if complex goal.

Based in Zug, Switzerland, the Longevity Science Foundation will prioritize four areas of research: personalized medicine, therapeutics, artificial intelligence (AI) and predictive diagnostics. The foundation accepts applications from any organization with a focus on funding early-stage academic research into the process of aging, known as geroscience. The mission for the projects it funds is to make a difference in peoples lives within five years.

The foundation has already raised an undisclosed amount to fund an initial round of projects and will continue raising the rest of its 860M ($1B) target over the next 10 years. Its setup expenses were covered by founders of LongeVC, a Swiss venture capital fund focused on the anti-aging niche. The Longevity Science Foundation board includes members of LongeVC in addition to research organizations including the National University of Singapore and Human Longevity in the US.

The goals of the foundation are ambitious, if the past decade or so in European biotech, fraught with delays and under-fulfilled promise in geroscience, is any indication. At the same time, they fit neatly into industry projections for the next decade, where sectors such as AI, gene therapy, and personalized medicine feature prominently.

The foundation is bent on taking head-on some of the major financing bottlenecks of translating geroscience research from the lab into clinical-stage anti-aging strategies, which is widely seen as a major boost for the thorny science of aging.

After spending five years in this sector it is so exciting to see substantial capital finally coming in to move the science forward, Greg Bailey, the CEO of the Dublin-based geroscience biotech Juvenescence, told me. This amount of capital and the quality of the individuals that are involved should be transformative to the trajectory of the science to modify aging.

The niche as a whole has had a bumpy ride in recent years. One example is the US company Unity Biotechnology, which is still reeling from a phase II clinical trial failure last year of its small molecule drug designed to treat osteoarthritis.

Unitys drug targeted the accumulation of senescent cells, which stop being able to perform their function with age and can drag entire organs and body systems down with them. The phase II setback called into question the viability of targeting senescent cells, though in July this year, the company touted promising phase I results of a similar drug for the treatment of age-related blindness conditions.

Investor interest in geroscience research has more broadly been hampered by the lack of a unified theory that explains all the different symptoms and conditions that characterize aging. Despite numerous attempts to identify biomarkers that can predict aging in recent years, no clear answer exists even to the question of whether aging is a disease or a catch-all term that includes a number of different processes. Additionally, aging itself isnt seen as an indication by major regulators including the EMA and FDA.

Other approaches to slowing down or reversing aging include repairing the chromosomes, which carry the genetic material of the cells; fixing the mitochondria, which are vital for cell metabolism; and replacing old tissue, especially by virtue of stem cell therapies. All these geroscience approaches carry potential risks as well as limitless promise.

Weve pivoted from a mitochondria-focused approach to cellular reprogramming, a powerful rejuvenation paradigm for cells, said Daniel Ives, the CEO of the UK biotech Shift Bioscience.

Cellular reprogramming is currently a goldilocks rejuvenation approach: too little and you have rejuvenation, too much and you risk cancer. Based on a novel application of machine learning, weve identified an opportunity to tame cellular reprogramming and safely reset cells and tissues back to a youthful state.

The Longevity Science Foundation aims to help scientists take on these issues by providing funds to early-stage researchers with no strings attached. It places a special emphasis on addressing inequalities: both in terms of patient access to cutting-edge treatments, and the access of scientists from diverse parts of the world and backgrounds to research funds.

We know a key barrier to these advancements and one of the most significant challenges facing longevity research today is the lack of transparent, equity-free funding for early-stage discovery and research, Garri Zmudze, a life sciences angel investor and the Executive Coordinator of the foundation, told me.

That is why, in all projects awarded funding by the Foundation, the [intellectual property] will remain the property of its respective researchers and owners. Donors will not, at this time, receive a financial stake in the research or IP.

The field, alongside many other medical niches, has seen an increase of investments in recent years. It also received a boost from a much-publicized trial of metformin, a diabetes drug that is also believed to have anti-aging properties. The TAME trial, which also aims to help discover reliable biomarkers for aging, is currently preparing to launch and will run for six years.

Many are hopeful that the Longevity Science Foundation, or at least geroscience research that comes out of the projects it awards, will help provide the next much-needed breakthrough.

In the short term, market approval of the first drug with an anti-aging or rejuvenation mechanism for an age-linked disease would mark a major milestone for the field, Ives said. In the medium term, the development of a safe but powerful rejuvenative drug would catalyze the regulatory change required to enable the approval of drugs with a full anti-aging or rejuvenation label.

Cover image via Anastasiia Slynko. Body text image via Shutterstock

Go here to read the rest:
Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu

Posted in Gene Medicine | Comments Off on Longevity Foundation to Fund Geroscience Research with 860M – Labiotech.eu

Page 721«..1020..720721722723..730740..»